文献速递消化道肿瘤与早癌

转移性胃癌图谱揭示铁死亡与疾病进展及免疫治疗应答的关联

Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response.
PubMed 文献 · Gastroenterology · 2024-08-02

该研究对68对初治原发与转移性胃腺癌标本进行单细胞转录组和免疫图谱分析,发现肝转移与腹膜转移的癌细胞特性和肿瘤微环境动态不同,转移灶中癌细胞通过上调GPX4逃避铁死亡。条件性敲除Gpx4或药物抑制铁死亡抵抗可减弱肿瘤生长和转移进展,铁死亡增敏治疗可增强嵌合抗原受体T细胞疗法疗效。

要点

  • 肝转移与腹膜转移的癌细胞特性及肿瘤微环境动态存在差异,支持转移部位癌细胞与局部微环境共同演化。
  • 胃腺癌进展中癌细胞通过上调GPX4逃避铁死亡,条件性敲除Gpx4或药物抑制铁死亡抵抗可减弱肿瘤生长和转移进展。
  • 铁死亡增敏治疗可增强嵌合抗原受体T细胞疗法的疗效。

核心结论

  • 靶向铁死亡防御联合嵌合抗原受体T细胞疗法可能成为具有潜在巨大临床意义的新型治疗策略。

研究设计与样本

  • 对68对初治原发与转移性胃腺癌标本进行深入的单细胞转录组和免疫图谱分析。
  • 采用细胞系、多个患者来源异种移植模型和新型胃腺癌小鼠模型进行体外和体内功能研究以验证观察结果。

主要发现

  • 肝转移和腹膜转移在癌细胞特性及肿瘤微环境表型动态方面表现出不同特征。
  • 不同转移灶中癌症元程序激活存在差异。
  • 胃腺癌进展中观察到癌细胞通过GPX4上调逃避铁死亡。
  • 条件性敲除Gpx4或药物抑制铁死亡抵抗显著减弱肿瘤生长和转移进展。
  • 铁死亡增敏治疗增强了嵌合抗原受体T细胞疗法的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metastases from gastric adenocarcinoma (GAC) lead to high morbidity and mortality. Developing innovative and effective therapies requires a comprehensive understanding of the tumor and immune biology of advanced GAC. Yet, collecting matched specimens from advanced, treatment-naïve patients with GAC poses a significant challenge, limiting the scope of current research, which has focused predominantly on localized tumors. This gap hinders deeper insight into the metastatic dynamics of GAC. METHODS: We performed in-depth single-cell transcriptome and immune profiling on 68 paired, treatment-naïve, primary metastatic tumors to delineate alterations in cancer cells and their tumor microenvironment during metastatic progression. To validate our observations, we conducted comprehensive functional studies both in vitro and in vivo, using cell lines and multiple patient-derived xenograft and novel mouse models of GAC. RESULTS: Liver and peritoneal metastases exhibited distinct properties in cancer cells and dynamics of tumor microenvironment phenotypes, supporting the notion that cancer cells and their local tumor microenvironments co-evolve at metastatic sites. Our study also revealed differential activation of cancer meta-programs across metastases. We observed evasion of cancer cell ferroptosis via GPX4 up-regulation during GAC progression. Conditional depletion of Gpx4 or pharmacologic inhibition of ferroptosis resistance significantly attenuated tumor growth and metastatic progression. In addition, ferroptosis-resensitizing treatments augmented the efficacy of chimeric antigen receptor T-cell therapy. CONCLUSIONS: This study represents the largest single-cell dataset of metastatic GACs to date. High-resolution mapping of the molecular and cellular dynamics of GAC metastasis has revealed a rationale for targeting ferroptosis defense in combination with chimeric antigen receptor T-cell therapy as a novel therapeutic strategy with potential immense clinical implications.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Cheng X, Dai E, Wu J, et al. Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response. Gastroenterology. 2024. PMID: 39097198. doi:10.1053/j.gastro.2024.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。